Day OneTuesday, 5 December 2023 - CST/CDT (Central Daylight, GMT-5)

Showing 1 of 1 Streams

General Session

7:30am - 8:15am

Breakfast and Networking

8:15am - 8:30amFree

Chairman's Opening and Welcome Remarks

Matthew Gibbs, Pharm.D., Independent Consultant

8:30am - 9:15amFree

Regulatory Update: The Changing Legal Environment in HealthCare

PBM Transparency Act of 2023
- Update: PBM Transparency Act of 2023 (FTC Investigation)
- What are the ramifications to come out of the transparency act?
- How is everyone doing business? State by state differentials
- Fully understanding the house energy committee's objectives
Continued insights on:
- Consolidated Appropriations Act
- Pharmacy Benefits Manager Accountability Act

Cami Agena, JD - Attorney, The Phoenix Law Group, LLC
Suzanne Broderick, JD - Attorney, The Phoenix Law Group, LLC

9:15am - 10:30amFree

The Latest on 340B Drug Pricing Program

Part 1: Fireside Chat: PROTECT 340B Act

Everything we need to know surrounding the PROTECT 340B Act

Part 2: : Resolving 340B challenges Through Innovative Market-Driven Solutions

The value of a 340B Clearinghouse to all relevant stakeholders.

Moving 340B discount administration from a direct purchase option to a rebate option

Bob Charles - Principal/Founder, The Generisys Company
Ann O'Brien - Vice President, Consultant Relations, Prime Therapeutics
Mesfin Tegenu - CEO and Chairman, RxParadigm

10:30am - 11:00am

Morning Networking and Refreshment Break

11:00am - 11:45amFree

Overview of the Average Manufacturer Price (AMP) Cap Removal Project in Relation to Insulin and Rebates

Why did some insulin manufacturers reduce their list prices and eliminate rebates?
Will other manufacturers follow suite?
Discuss the AMP Cap removal Project as part of the American Rescue Plan Act
Address insulin manufacturers recent announcement of insulin price reductions and other market implications

Andrew Timcheck, CERA, FSA, MAAA - Senior Consulting Actuary, Milliman
Hiram Satterwhite, FSA, MAAA - Senior Consulting Actuary, Milliman

11:45am - 12:30pmFree

Fireside Chat: Rebates - What Are We Doing?

If we can’t get rid of rebates, how can we get cheaper therapeutics into the hands of the consumer and who should be paying?
Discuss how rebates will price with biosimilars
Analysis of the economics and downstream consequences of rebates

Suzette DiMascio, CHE, CMCE, CPC - Vice President, FFF Enterprises
Tyrone Squires, CPBS - Managing Director, TransparentRx

12:30pm - 1:30pm

Networking Lunch in the Exhibit Hall

1:30pm - 2:15pmFree

Are They Slowing Down? Copay Maximizer Programs

Understanding copay maximizer and patient assistance programs
- What they are and what they mean
- Why aren’t they noticeable in insurance policies?
What they mean for specialty and rare disease
- What impact will this have on pharma and other players?
Review H.R. 830 and its effects

2:15pm - 2:55pmFree

Financial Acceptance and Consequences of Biosimilars and Specialty Therapeutics

Understanding the costs of biosimilars, specialty therapeutics, insulin etc.
- How do you cover rising costs?
Why it's critical to look outside of the scope of copay benefits?

Justin Jasniewski - Chief Executive Officer, Serve You Rx

2:55pm - 3:35pm

Combatting Spread Pricing with Optimal PBM Contracting and Pricing

Spread pricing: what it is, how does it impact claim pricing, and examples
Assessing the impact of spread pricing…how to compare your pricing to competitive values
The value of benchmark schedules such as NADAC
RFP and contracting strategies
Legislative initiatives: requirements and likely impact on the market
Oral specialty generics: a high impact factor in future generic costs
Summary: Maximizing Value in Generic Drugs: Now and the Future

Terrance Killilea, PharmD - Partner, Senior Vice President, Clinical, Fiscal Integration, USI Insurance Services

3:35pm - 4:05pm

Networking and Refreshment Break

4:05pm - 4:45pm

The Expanding Role of Data

What the role of data means for patient insights and cost of care management
Drive collaborative market access innovation through data and analytics exchange
Looking ahead: how to utilize data when optimizing patient access in 2024

Paul Dempsey - National Account Director, Obesity, Novo Nordisk
Wes Smith, FSA, CERA, MAAA - Vice President, Analytics and Reporting, AffirmedRx

4:45pm - 5:30pm

Joining Forces - Healthcare Mergers and Acquisitions

Discuss and review new PBM technology solutions in the market
With the surge of swift change, what will 2024 entail?
Overview of the integration of accreditation and medically integrated pharmacies

Brian Davis, M.S., RPh - Pharmacy Strategy and Partnerships, University of California Health

5:30pm - 6:30pm

Reception